MA08.072p, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
Independence Blue Cross updated MA08.072p to revise medical necessity criteria for bevacizumab and biosimilars across 11 cancer indications, aligning with current FDA labeling and NCCN guidelines. Three new ICD-10 codes were added (including inflammatory breast cancer and HER2 negative status), four uncertain behavior ovarian codes were removed, and a new HCPCS code Q5160 (bevacizumab-nwgd/Jobevne) was added to the covered biosimilar portfolio.